Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation

被引：2

作者：

Nakamae, Hirohisa ^{[1
]}

机构：

[1] Osaka Metropolitan Univ, Grad Sch Med, Dept Hematol, Osaka, Japan

来源：

FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷

基金：

日本学术振兴会;

关键词：

post-transplant cyclophosphamide (PTCy); allogeneic hematopoietic cell transplantation (allo-HCT); HLA-haploidentical transplantation; HLA-matched transplantation; graft-versus-tumor (GVT) effect; LEUKEMIA WORKING PARTY; REPLETE HAPLOIDENTICAL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; BLOOD STEM-CELLS; T-CELL; PERIPHERAL-BLOOD; HOST-DISEASE; EUROPEAN-SOCIETY; DONOR AGE; HEMATOLOGIC MALIGNANCIES;

D O I：

10.3389/fimmu.2024.1403936

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Post-transplant cyclophosphamide (PTCy) is becoming the standard prophylaxis for graft-versus-host disease (GVHD) in HLA-haploidentical allogeneic hematopoietic cell transplantation (allo-HCT) and in HLA-matched allo-HCT. Immune reconstitution in the post-transplant setting may influence the graft-versus-tumor (GVT) effect because PTCy has a profound effect on T cell and natural killer cell functions and their reconstitution after allo-HCT. However, many recent studies have shown that the incidence of relapse after allo-HCT with PTCy is comparable to that after conventional allo-HCT. To further improve the outcomes, it is critical to establish a strategy to maintain or effectively induce the GVT effect when using PTCy as a platform for GVHD prophylaxis. However, there is a paucity of studies focusing on the GVT effect in allo-HCT with PTCy. Therefore, focusing on this issue may lead to the establishment of more appropriate strategies to improve transplantation outcomes without exacerbating GVHD, including novel therapies involving cell modification.

引用

页数：14

共 114 条

[41] Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent [J].

Kanakry, Christopher G. ;

Ganguly, Sudipto ;

Luznik, Leo .

ONCOIMMUNOLOGY, 2015, 4 (03) :1-3

[42] Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide [J].

Kanakry, Christopher G. ;

Ganguly, Sudipto ;

Zahurak, Marianna ;

Bolanos-Meade, Javier ;

Thoburn, Christopher ;

Perkins, Brandy ;

Fuchs, Ephraim J. ;

Jones, Richard J. ;

Hess, Allan D. ;

Luznik, Leo .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (211)

[43] Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation [J].

Khimani, Farhad ;

Ranspach, Peter ;

Elmariah, Hany ;

Kim, Jongphil ;

Whiting, Junmin ;

Nishihori, Taiga ;

Locke, Frederick L. ;

Perez, Ariel Perez ;

Dean, Erin ;

Mishra, Asmita ;

Perez, Lia ;

Lazaryan, Aleksandr ;

Jain, Michael D. ;

Nieder, Michael ;

Liu, Hein ;

Faramand, Rawan ;

Hansen, Doris ;

Alsina, Melissa ;

Ochoa, Leonel ;

Davila, Marco ;

Anasetti, Claudio ;

Pidala, Joseph ;

Bejanyan, Nelli .

TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (11) :940-948

[44] Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation [J].

Lee, Catherine J. ;

Savani, Bipin N. ;

Mohty, Mohamad ;

Labopin, Myriam ;

Ruggeri, Annalisa ;

Schmid, Christoph ;

Baron, Frederic ;

Esteve, Jordi ;

Gorin, Norbert C. ;

Giebel, Sebastian ;

Ciceri, Fabio ;

Nagler, Arnon .

HAEMATOLOGICA, 2017, 102 (11) :1810-1822

[45]

Lee N, 1998, J IMMUNOL, V160, P4951

[46] Time series clustering of T cell subsets dissects heterogeneity in immune reconstitution and clinical outcomes among MUD-HCT patients receiving ATG or PTCy [J].

Leserer, Saskia ;

Graf, Theresa ;

Franke, Martina ;

Bogdanov, Rashit ;

Arrieta-Bolanos, Esteban ;

Buttkereit, Ulrike ;

Leimkuehler, Nils ;

Fleischhauer, Katharina ;

Reinhardt, Hans Christian ;

Beelen, Dietrich W. ;

Turki, Amin T. T. .

FRONTIERS IN IMMUNOLOGY, 2023, 14

[47] Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification [J].

Li, Yun ;

Wang, Na ;

Zhang, Xiaoying ;

Cao, Yang ;

Zhang, Lingfeng ;

Liu, Aiguo ;

Zhang, Yicheng .

BLOOD REVIEWS, 2023, 62

[48] HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide [J].

Luznik, Leo ;

O'Donnell, Paul V. ;

Symons, Heather J. ;

Chen, Allen R. ;

Leffell, M. Susan ;

Zahurak, Marianna ;

Gooley, Ted A. ;

Piantadosi, Steve ;

Kaup, Michele ;

Ambinder, Richard F. ;

Huff, Carol Ann ;

Matsui, William ;

Bolanos-Meade, Javier ;

Borrello, Ivan ;

Powell, Jonathan D. ;

Harrington, Elizabeth ;

Warnock, Sandy ;

Flowers, May ;

Brodsky, Robert A. ;

Sandmaier, Brenda M. ;

Storb, Rainer F. ;

Jones, Richard J. ;

Fuchs, Ephraim J. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (06) :641-650

[49] High-dose cyclophosphamide for graft-versus-host disease prevention [J].

Luznik, Leo ;

Jones, Richard J. ;

Fuchs, Ephraim J. .

CURRENT OPINION IN HEMATOLOGY, 2010, 17 (06) :493-499

[50] CD34+cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT) [J].

Maffini, Enrico ;

Labopin, Myriam ;

Blaise, Didier ;

Ciceri, Fabio ;

Gulbas, Zafer ;

Deconinck, Eric ;

Leblond, Veronique ;

Chevallier, Patrick ;

Socie, Gerard ;

Araujo, Mercedes C. ;

Koc, Yener ;

Savani, Bipin N. ;

Gorin, Norbert C. ;

Lanza, Francesco ;

Nagler, Arnon ;

Mohty, Mohamad .

AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (08) :892-899

← 1 2 3 4 5 6 7 8 9 10 →